BREAST: ATEMPT 2.0
Trial ID
NCT04893109
Trial Sponsor
Dana-Farber Cancer Institute
A Randomized Phase II Trial of Adjuvant Trastuzumab Emtansine (T-DM1) Followed by Subcutaneous Trastuzumab Versus Paclitaxel in Combination With Subcutaneous Trastuzumab for Stage I HER2-positive Breast Cancer